Personalis Inc., a US-based cancer genomics company has announced to have signed a joint venture agreement with MapKure, LLC, a newly created entity owned by SpringWorks and BeiGene, that focuses solely on genetic disease drivers.
The partnership is intended for a clinical trial assay (CTA) relying on Personalis NeXT Platform, to augment the progression of BGB-3245, an experimental next-gen B-RAF inhibitor for the treatment of advanced and refractory solid tumor.
MapKure will be teaming up with Personalis to use its NeXT Platform as a final test for patients registered in MapKure’s Phase 1A and 1B dose expansion and escalation clinical trial. Additionally, MapKure will be able to take advantage of the breadth of Personalis’ NeXT Platform, which facilitates broad tumor immunogenomic profiling and combines multiple biomarker assays into one.
This will enable multidimensional viewing of the tumor and its microenvironment from a single specimen, which can further help MapKure determine if other biomarkers are clinically associated with BGB-3245.
Chief Executive Officer of Personalis, John West was quoted saying that, new cancer combination therapies and immunotherapy promote the need for the development of advanced composite biomarkers that replicate the complex biology while driving resistance and response to cancer therapy.
The NeXT Platform delivers extensive genomic information from the transcriptome & exome while providing information that can aid the identification of new biomarkers for biotechnology specialists such as MapKure.
Once MapKure selects these biomarkers, the company plans to further them as companion diagnostics for regulatory approval and submission, cited the CEO, while adding that Personalis looks forward to its collaboration with MapKure so that it can accelerate the development of cancer therapy in the clinic by exacting results from Personalis NeXT Platform.
Personalis conducts one of the largest sequencing operations in the world and is currently the only sequencing provider to the VA MVP, while MapKure is a clinical-stage company formed in 2019 to develop precision medicines to manage life-threatening diseases such as cancer.
Source Link –